tirzepatide in france becomes first EU country to reimburse anti-obesity drugs Lilly releases Zepbound® (tirzepatide) single-dose

Zepbound carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

10.1016/S0140-6736(06)69705-5 51 DruckerD

Two medicines that influence appetite can create layered effects, even when each one seems understandable on its own

Numan Health

Retatrutide stands out by targeting multiple receptors responsible for hunger and glycemic control, offering a potentially more holistic approach to treatment

RELATED: Gastritis Explained: What It Is, What Causes It, and How to Treat It t Is, What Causes It, and How to Treat It The Physiology of Loss: Differentiating Fat vs